Firocoxib Safety and Efficacy Trial Completed in 429 Horses

In a recently completed 429-horse trial, researchers reinforced the effectiveness and safety profile of Equioxx (firocoxib), the first equine oral, nonsteroidal anti-inflammatory drug (NSAID) to be approved in more than 20 years.

"This research helps prove the benefits of Equioxx, and it also demonstrates the commitment to continued research for all Merial products," said Doug Carithers, DVM, director of marketing trials and publications at Merial. "This is one of the largest equine NSAID studies conducted after product launch, and the results validate what we know veterinarians and owners nationwide see in horses after using Equioxx."

Equioxx is proven to control the joint pain and inflammation associated with equine osteoarthritis, which is one of the most common causes of lameness in horses. Also known as degenerative joint disease, osteoarthritis can develop in horses as young as 2 years old.

From May 2007 to February 2008, horses diagnosed with osteoarthritis were enrolled in the Equioxx Experience Trial by veterinarians at 80 sites in 25 states. The study included horses from 1 to 33 years old, representing more than 10 breeds. After a 14-day trial of Equioxx, both veterinarians and their handlers reported results. Some of the key findings include:

  • Improvement continued through duration of 14-day trial
  • Improvement was consistent regardless of breed, age, or weight of horse
  • Improvement was consistent regardless of the joint(s) involved
  • 87.6% of handlers reported horses as "moving better"
  • 96% of handlers believed Equioxx was palatable for their horse(s)

The trial evaluated horses with both single- and multiple-joint osteoarthritis diagnoses. Of those cases, 50% of horses were diagnosed with osteoarthritis in the tarsus (hock) joint, and more than 27% of horses showed osteoarthritis in the fetlock joint.

In previous research, Equioxx was shown to work quickly to provide 24 hours of pain relief and is easily administered as an oral paste.

Since its launch in 2007, Equioxx is the only NSAID approved for use up to 14 consecutive days by the American Quarter Horse Association (AQHA) and United States Equestrian Federation (USEF) when used at the recommended dose.

"We believe in demonstrating the results of Equioxx in practical, everyday situations both with continued research and with customers across the country," Carithers said.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from Learn More